Related Experiment Video
Updated: Jul 18, 2026

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements
Published on: July 29, 2021
Nitric oxide in hypertension
Matthias Hermann1, Andreas Flammer, Thomas F Lüscher
1Department of Cardiology, the Cardiovascular Center, University Hospital Zurich, Switzerland.
Insights
Endothelial dysfunction, marked by impaired nitric oxide (NO) bioavailability, is a key factor in hypertension and cardiovascular disease. Understanding NO
Area of Science:
- Cardiovascular Science
- Endocrinology
- Nephrology
Background:
- Hypertension is a primary risk factor for cardiovascular disease.
- Endothelial dysfunction, characterized by impaired nitric oxide (NO) bioavailability, links hypertension and cardiovascular disease.
- NO plays a critical role in blood pressure regulation.
Purpose of the Study:
- To explore the role of endothelial dysfunction and impaired NO bioavailability in hypertension.
- To investigate the mechanisms linking NO bioactivity to blood pressure regulation.
- To highlight the therapeutic implications of understanding NO mechanisms in hypertension.
Main Methods:
- Review of evidence linking NO bioactivity to hypertension.
- Analysis of genetic studies (e.g., endothelial NO synthase gene disruption in mice).
- Examination of clinical studies on vasodilatory responses and NO inhibition in hypertensive patients.
Main Results:
- Endothelial dysfunction and impaired NO bioavailability are significant contributors to hypertension.
- Genetic models show elevated blood pressure with disrupted endothelial NO synthase.
- Hypertensive patients exhibit blunted responses to vasodilators, and NO inhibition raises blood pressure.
- Impaired NO bioactivity is associated with arterial stiffness and systolic hypertension.
Conclusions:
- Impaired NO bioactivity is a crucial factor in the development and progression of hypertension.
- Understanding the mechanisms of NO bioactivity impairment is vital for developing novel hypertension treatments.
- Targeting NO pathways may offer new therapeutic strategies for managing hypertension and cardiovascular risk.
Abstract:
Hypertension is a major risk factor for cardiovascular disease, and reduction of elevated blood pressure significantly reduces the risk of cardiovascular events. Endothelial dysfunction, which is characterized by impairment of nitric oxide (NO) bioavailability, is an important risk factor for both hypertension and cardiovascular disease and may represent a major link between the conditions. Evidence suggests that NO plays a major role in regulating blood pressure and that impaired NO bioactivity is an important component of hypertension. Mice with disruption of the gene for endothelial NO synthase have elevated blood pressure levels compared with control animals, suggesting a genetic component to the link between impaired NO bioactivity and hypertension. Clinical studies have shown that patients with hypertension have a blunted arterial vasodilatory response to infusion of endothelium-dependent vasodilators and that inhibition of NO raises blood pressure. Impaired NO bioactivity is also implicated in arterial stiffness, a major mechanism of systolic hypertension. Clarification of the mechanisms of impaired NO bioactivity in hypertension could have important implications for the treatment of hypertension.
More Related Videos
Related Concept Videos
Nitric Oxide Signaling Pathway
Antihypertensive Drugs: Vasodilators
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Hypertension II: Pathophysiology
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Disorders of the Autonomic Nervous System
Raynaud's disease, also known as Raynaud's phenomenon, is a...

